Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Monopar Therapeutics Inc. (NASDAQ:MNPR) stock is skyrocketing on Thursday.

The company agreed with AstraZeneca Plc’s (NASDAQ:AZN) Alexion for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson’s disease.

Monopar will be responsible for all future global development and commercialization activities.

Also Read: Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today

Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and pre-determined regulatory and sales milestones.

Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised. It affects one in 30,000 live births ...